Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2016

01-07-2016 | Mini-Review

Glucagon: acute actions on hepatic metabolism

Authors: Russell A. Miller, Morris J. Birnbaum

Published in: Diabetologia | Issue 7/2016

Login to get access

Abstract

Type 2 diabetes mellitus is the result of impaired systemic control of glucose homeostasis, in part through the dysregulation of the hormone glucagon. Glucagon acts on the liver to increase glucose production through alterations in hepatic metabolism, and reducing the elevated glucagon signalling in diabetic patients is an attractive strategy for the treatment of hyperglycaemia. Here we review the actions of the hormone in the liver, focusing on the acute alterations of metabolic pathways. This review summarises a presentation given at the ‘Novel data on glucagon’ symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Mona Abraham and Tony Lam, DOI: 10.​1007/​s00125-016-3950-3, and by Young Lee and colleagues, DOI: 10.​1007/​s00125-016-3965-9) and an overview by the Session Chair, Isabel Valverde (DOI: 10.​1007/​s00125-016-3946-z).
Literature
1.
Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059PubMed
2.
Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253–283CrossRefPubMed
3.
4.
Kelly RP, Garhyan P, Raddad E et al (2015) Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab 17:414–422CrossRefPubMed
5.
Mu J, Jiang G, Brady E et al (2011) Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 54:2381–2391CrossRefPubMed
6.
Mu J, Qureshi SA, Brady EJ et al (2012) Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One 7:e49572CrossRefPubMedPubMedCentral
7.
Petersen KF, Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018–2024CrossRefPubMed
8.
Sammons MF, Lee EC (2015) Recent progress in the development of small-molecule glucagon receptor antagonists. Bioorg Med Chem Lett 25:4057–4064CrossRefPubMed
9.
Sutherland EW, Wosilait WD (1956) The relationship of epinephrine and glucagon to liver phosphorylase. I. Liver phosphorylase; preparation and properties. J Biol Chem 218:459–468PubMed
10.
Berthet J, Rall TW, Sutherland EW (1957) The relationship of epinephrine and glucagon to liver phosphorylase. IV. Effect of epinephrine and glucagon on the reactivation of phosphorylase in liver homogenates. J Biol Chem 224:463–475PubMed
11.
Miller LL (1961) Some direct actions of insulin, glucagon, and hydrocortisone on the isolated perfused rat liver. Recent Prog Horm Res 17:539–568PubMed
12.
Sokal JE (1966) Effect of glucagon on gluconeogenesis by the isolated perfused rat liver. Endocrinology 78:538–548CrossRefPubMed
13.
14.
Burgess SC, He T, Yan Z et al (2007) Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab 5:313–320CrossRefPubMedPubMedCentral
15.
Exton JH, Park CR (1969) Control of gluconeogenesis in liver. 3. Effects of l-lactate, pyruvate, fructose, glucagon, epinephrine, and adenosine 3ʹ,5ʹ-monophosphate on gluconeogenic intermediates in the perfused rat liver. J Biol Chem 244:1424–1433PubMed
16.
Exton JH, Park CR (1968) Control of gluconeogenesis in liver. II. Effects of glucagon, catecholamines, and adenosine 3ʹ,5ʹ-monophosphate on gluconeogenesis in the perfused rat liver. J Biol Chem 243:4189–4196PubMed
17.
Exton JH, Corbin JG, Park CR (1969) Control of gluconeogenesis in liver. IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver. J Biol Chem 244:4095–4102PubMed
18.
19.
Titanji VP, Zetterqvist O, Engstroom L (1976) Regulation in vitro of rat liver pyruvate kinase by phosphorylation-dephosphorylation reactions, catalyzed by cyclic-AMP dependent protein kinases and a histone phosphatase. Biochim Biophys Acta 422:98–108CrossRefPubMed
20.
El-Maghrabi MR, Claus TH, Pilkis J, Fox E, Pilkis SJ (1982) Regulation of rat liver fructose 2,6-bisphosphatase. J Biol Chem 257:7603–7607PubMed
21.
Exton JH (1987) Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab Rev 3:163–183CrossRefPubMed
22.
Fukita Y, Gotto AM, Unger RH (1975) Basal and postprotein insulin and glucagon levels during a high and low carbohydrate intake and their relationships to plasma triglycerides. Diabetes 24:552–558CrossRefPubMed
23.
Flakoll PJ, Borel MJ, Wentzel LS, Williams PE, Lacy DB, Abumrad NN (1994) The role of glucagon in the control of protein and amino acid metabolism in vivo. Metab Clin Exp 43:1509–1516CrossRefPubMed
24.
25.
Liang Y, Osborne MC, Monia BP et al (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410–417CrossRefPubMed
26.
Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ (2011) Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol (Oxf) 74:593–598CrossRef
27.
Fehlmann M, Le Cam A, Freychet P (1979) Insulin and glucagon stimulation of amino acid transport in isolated rat hepatocytes. Synthesis of a high affinity component of transport. J Biol Chem 254:10431–10437PubMed
28.
Gebhardt R, Kleemann E (1987) Hormonal regulation of amino acid transport system N in primary cultures of rat hepatocytes. Eur J Biochem 166:339–344CrossRefPubMed
29.
Lim SK, Cynober L, De Bandt JP, Aussel C (1999) A Na+-dependent system A and ASC-independent amino acid transport system stimulated by glucagon in rat hepatocytes. Cell Biol Int 23:7–12CrossRefPubMed
30.
Wolfe BM, Culebras JM, Aoki TT et al (1979) The effects of glucagon on protein metabolism in normal man. Surgery 86:248–257PubMed
31.
Lacey JH, Bradford NM, Joseph SK, McGivan JD (1981) Increased activity of phosphate-dependent glutaminase in liver mitochondria as a result of glucagon treatment of rats. Biochem J 194:29–33CrossRefPubMedPubMedCentral
32.
Gerich JE, Meyer C, Stumvoll MW (2000) Hormonal control of renal and systemic glutamine metabolism. J Nutr 130:995S–1001SPubMed
33.
Uchida C, Funai T, Oda T, Ohbayashi K, Ichiyama A (1994) Regulation by glucagon of serine: pyruvate/alanine: glyoxylate aminotransferase gene expression in cultured rat hepatocytes. J Biol Chem 269:8849–8856PubMed
34.
Xue HH, Fujie M, Sakaguchi T et al (1999) Flux of the l-serine metabolism in rat liver. The predominant contribution of serine dehydratase. J Biol Chem 274:16020–16027CrossRefPubMed
35.
Pryor HJ, Smyth JE, Quinlan PT, Halestrap AP (1987) Evidence that the flux control coefficient of the respiratory chain is high during gluconeogenesis from lactate in hepatocytes from starved rats. Implications for the hormonal control of gluconeogenesis and action of hypoglycaemic agents. Biochem J 247:449–457CrossRefPubMedPubMedCentral
36.
Yamazaki RK (1975) Glucagon stimulation of mitochondrial respiration. J Biol Chem 250:7924–7930PubMed
37.
Yamazaki RK, Mickey DL, Story M (1980) Rapid action of glucagon on hepatic mitochondrial calcium metabolism and respiratory rates. Biochim Biophys Acta 592:1–12CrossRefPubMed
38.
Breton L, Clot JP, Baudry M (1983) Effects of glucagon on basal metabolic rate and oxidative phosphorylation of rat liver mitochondria. Horm Metab Res 15:429–432CrossRefPubMed
39.
Bartlett PJ, Gaspers LD, Pierobon N, Thomas AP (2014) Calcium-dependent regulation of glucose homeostasis in the liver. Cell Calcium 55:306–316CrossRefPubMed
40.
Combettes L, Berthon B, Binet A, Claret M (1986) Glucagon and vasopressin interactions on Ca2+ movements in isolated hepatocytes. Biochem J 237:675–683CrossRefPubMedPubMedCentral
41.
Fernando KC, Gregory RB, Barritt GJ (1998) Protein kinase A regulates the disposition of Ca2+ which enters the cytoplasmic space through store-activated Ca2+ channels in rat hepatocytes by diverting inflowing Ca2+ to mitochondria. Biochem J 330:1179–1187CrossRefPubMedPubMedCentral
42.
Joseph SK, Ryan SV (1993) Phosphorylation of the inositol trisphosphate receptor in isolated rat hepatocytes. J Biol Chem 268:23059–23065PubMed
43.
Cardenas C, Miller RA, Smith I et al (2010) Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 142:270–283CrossRefPubMedPubMedCentral
44.
McCormack JG (1985) Studies on the activation of rat liver pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase by adrenaline and glucagon. Role of increases in intramitochondrial Ca2+ concentration. Biochem J 231:597–608CrossRefPubMedPubMedCentral
45.
Denton RM, McCormack JG (1980) The role of calcium in the regulation of mitochondrial metabolism. Biochem Soc Trans 8:266–268CrossRefPubMed
46.
Denton RM, McCormack JG, Edgell NJ (1980) Role of calcium ions in the regulation of intramitochondrial metabolism. Effects of Na+, Mg2+ and ruthenium red on the Ca2+-stimulated oxidation of oxoglutarate and on pyruvate dehydrogenase activity in intact rat heart mitochondria. Biochem J 190:107–117CrossRefPubMedPubMedCentral
47.
Strzelecki T, Strzelecka D, Koch CD, LaNoue KF (1988) Sites of action of glucagon and other Ca2+ mobilizing hormones on the malate aspartate cycle. Arch Biochem Biophys 264:310–320CrossRefPubMed
48.
Sugano T, Nishimura K, Sogabe N et al (1988) Ca2+-dependent activation of the malate-aspartate shuttle by norepinephrine and vasopressin in perfused rat liver. Arch Biochem Biophys 264:144–154CrossRefPubMed
49.
Amigo I, Traba J, Gonzalez-Barroso MM et al (2013) Glucagon regulation of oxidative phosphorylation requires an increase in matrix adenine nucleotide content through Ca2+ activation of the mitochondrial ATP-Mg/Pi carrier SCaMC-3. J Biol Chem 288:7791–7802CrossRefPubMedPubMedCentral
50.
Kazda CM, Garhyan P, Kelly RP et al (2015) A randomized, double-blind, placebo-controlled phase 2 study of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. Diabetes Care. doi:10.​2337/​dc15-1643 PubMed
Metadata
Title
Glucagon: acute actions on hepatic metabolism
Authors
Russell A. Miller
Morris J. Birnbaum
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3955-y

Other articles of this Issue 7/2016

Diabetologia 7/2016 Go to the issue

Article

Inactivation of class II PI3K-C2α induces leptin resistance, age-dependent insulin resistance and obesity in male mice

Article

Differential regulation of serum microRNA expression by HNF1β and HNF1α transcription factors

MINI-Review

Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark

Article

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial

Mini-review

Glucagon is the key factor in the development of diabetes

Letter

The intriguing relationship between epilepsy and type 1 diabetes mellitus. Reply to Sander JW, Novy J, Keezer MR [letter]

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits